• Moderna (NasdaqGS:MRNA) ranked no. 1 on TIME's 2026 World's Most Impactful Companies list.
• The company received European approval for mCOMBRIAX, its first combined flu and COVID vaccine.
• These developments expand Moderna's recognized societal role and add a new approved product beyond COVID-only vaccines.

For investors following Moderna, this recognition and new approval come as the company continues to build around its mRNA platform in vaccines and therapeutics. The flu plus COVID product adds another element to its commercial footprint, which has previously centered on COVID-19. The news also connects to broader interest in respiratory vaccines and combination shots.

The key questions for you as an investor are likely to center on uptake of mCOMBRIAX in Europe and what it signals for future combination products. These developments may also influence how the market views Moderna's efforts to broaden its pipeline beyond a single core product category.

Stay updated on the most important news stories for Moderna by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Moderna.

Investor Checklist

Quick Assessment

• ⚖️ Price vs Analyst Target: At US$50.42, Moderna trades about 16% above the US$43.37 analyst price target range midpoint.
• ⚖️ Simply Wall St Valuation: Valuation status is listed as unknown, so treat the stock as an open question rather than clearly cheap or expensive.
• ❌ Recent Momentum: The stock is down 0.5% over the last 30 days, so this news has not translated into short term gains yet.

There is only one way to know the right time to buy, sell or hold Moderna. Head to Simply Wall St's company report for the latest analysis of Moderna's Fair Value.

Key Considerations

• 📊 TIME's ranking and the European approval for the flu plus COVID vaccine support Moderna's profile as more than a single product COVID player.
• 📊 Watch early prescription trends, pricing, and any commentary on European rollout for mCOMBRIAX, as well as updates on other combo or respiratory candidates.
• ⚠️ Moderna is loss making, with a reported loss of US$3,194.0m and a P/E of 6.26 on a loss basis, so execution on the new product will be important for the path to profitability.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Moderna analysis. Alternatively, you can check out the community page for Moderna to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.